RT Journal Article
SR Electronic
T1 Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
JF Sexually Transmitted Infections
JO Sex Transm Infect
FD BMJ Publishing Group Ltd
SP 32
OP 37
DO 10.1136/sextrans-2020-054718
VO 98
IS 1
A1 Sylvia Kusemererwa
A1 Andrew Abaasa
A1 Anita Kabarambi
A1 Martin Onyango
A1 Joseph Okello Mugisha
YR 2022
UL http://sti.bmj.com/content/98/1/32.abstract
AB Objectives Participation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.Methods We used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at baseline and quarterly for 2 years. Risk compensation was defined as a significant increase (trend p<0.05) in the proportion of women reporting risky sexual behaviour or a diagnosed STI between baseline and end of follow-up.Results Between September 2013 and December 2016, 197 women (active arm: n=132 and placebo: n=65) were enrolled at the Masaka site. There were decreases in all markers of sexual risk behaviour with statistically significant decreases in only the proportion of women reporting ≥2 sexual partners, p=0.026 and those diagnosed with Trichomonas vaginalis p<0.001 and or Neisseria gonorrhoeae p<0.001Conclusions No evidence of risk compensation was observed in this trial.Trial registration number NCT01539226.Data are available on reasonable request.